Cytotoxic T lymphocytes (M.D. Anderson Cancer Center)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCytotoxic T lymphocytes (M.D. Anderson Cancer Center)
Drug Alias NameCTLs细胞毒性T淋巴细胞细胞毒性T淋巴细胞-M.D. Anderson Cancer Center
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsBK Polyomavirus InfectionsNeoplasmsCarcinoma, Merkel Cell +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsBK Polyomavirus InfectionsCarcinoma, Merkel CellPolyomavirus Infections +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A